Pentoxifylline

Non-selective phosphodiesterase inhibitor with hemorheological properties. Increases red blood cell deformability, reduces blood viscosity, and decreases fibrinogen levels. Also inhibits TNF-alpha production and has anti-inflammatory effects independent of its rheological actions. Improves microcirculatory blood flow in tissues with compromised perfusion.

Half-life

0.4-0.8 hours (active metabolites 1-1.6 hours)

Bioavailability

20-30% (oral, extensive first-pass)

Route

oral

Evidence tier

T2 — Single-RCT or mechanistic

Optimization pillars

cellular-health · recovery

References

3 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

400 mg/day

Low-dose anti-inflammatory

moderate

400 mg TID

Standard peripheral vascular dosing

aggressive

400 mg TID with extended-release

Maximum dosing with meals

Monitoring

hs-crp
hematocrit
hemoglobin
creatinine
alt
ast

Contraindications

recent-cerebral-hemorrhage
retinal-hemorrhage
severe-hepatic-impairment
active-bleeding

References

PMID:22419336Pentoxifylline for alcoholic hepatitis — Cochrane Database Syst Rev, 2012
PMID:23447039Pentoxifylline for renal protection in diabetic kidney disease: a model of old drugs for new horizons — Ann Intern Med, 2013
PMID:9067553Pentoxifylline for intermittent claudication: systematic review — BMJ, 1997

Notes

Pentoxifylline is the compound nobody talks about that solves a problem everybody ignores. Blood viscosity. Men on TRT with elevated hematocrit are walking around with blood that flows like syrup through their capillary beds. Pentoxifylline makes red blood cells more deformable, reduces fibrinogen-driven aggregation, and improves microcirculatory flow. The 36-minute parent half-life looks alarming until you realize the active metabolites last 1-2 hours and the rheological effects persist for the duration of therapy. Three-times-daily dosing is necessary because of that short half-life. The TNF-alpha inhibition provides a secondary anti-inflammatory benefit that has shown renal protective effects in diabetic kidney disease. Tier 2 because the evidence for its use in the optimization context is extrapolated from peripheral vascular disease and hepatology data, not from direct enhancement trials.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Pentoxifylline in a protocol matched to you